Project Description

Sigyn Therapeutics
Providing Shelter From The Gathering Cytokine Storm

Date & Time:

February 16, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Sigyn Therapy (OTCPink: SIGY) is a new treatment for life-threatening conditions that stem from Cytokine Storm Syndrome including Sepsis, which is not currently being addressed with an approved therapy.

According to The Lancet, there were 48.9 million cases of Sepsis and 11 million deaths globally in 2017. Sepsis kills more people around the world than all forms of cancer combined. In the United States, Sepsis is the most common cause of in-hospital deaths with annual costs exceeding $24 billion.

Sigyn Therapy is a single-use disposable device designed to work with dialysis machines already in hospitals and clinics worldwide. It filters pro-inflammatory cytokines and endotoxins from the bloodstream. This rebalances the immune system and allows the body to fight fight Sepsis. Led by an experienced team of device developers, Sigyn Therapeutics is currently seeking approval for an IDE in the United States.

Join our webinar on February 16 to hear from Sigyn Therapeutics’ CEO, James Joyce, on how Sigyn is poised to help save millions of lives and billions of dollars with its breakthrough device.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.